Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Japanese pharma firms are changing the long-standing practice of out-licensing products in the U.S., with maturing U.S. operations now directly developing more than a dozen drugs in or near Phase III.

Related Content

Daiichi Sankyo Will Focus R&D; Cardio Is Heart Of Combined Pipeline
Replidyne faropenem NDA in 2005
Daiichi, Sankyo Deal Will Fend Off Foreign Competition In Japan, Build In U.S.
Teva/Eisai rasagiline deal





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts